CeriBell, Inc. (NASDAQ:CBLL - Get Free Report) Director Josef Parvizi sold 25,000 shares of the stock in a transaction dated Monday, November 16th. The shares were sold at an average price of $26.02, for a total transaction of $650,500.00. Following the completion of the transaction, the director owned 882,911 shares of the company's stock, valued at $22,973,344.22. This represents a 2.75% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
CeriBell Price Performance
CeriBell stock traded down $0.45 during trading hours on Tuesday, hitting $25.97. 428,155 shares of the company traded hands, compared to its average volume of 590,738. CeriBell, Inc. has a 1-year low of $12.65 and a 1-year high of $28.89. The firm has a market cap of $1.01 billion, a P/E ratio of -13.39 and a beta of 0.86. The firm's 50-day simple moving average is $25.59 and its two-hundred day simple moving average is $21.10. The company has a quick ratio of 7.79, a current ratio of 8.18 and a debt-to-equity ratio of 0.17.
CeriBell (NASDAQ:CBLL - Get Free Report) last issued its quarterly earnings results on Tuesday, November 3rd. The company reported ($0.55) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.04). The company had revenue of $29.34 million during the quarter, compared to analyst estimates of $29.18 million. CeriBell had a negative return on equity of 52.59% and a negative net margin of 67.96%. As a group, analysts forecast that CeriBell, Inc. will post -2.05 earnings per share for the current fiscal year.
Institutional Trading of CeriBell
A number of large investors have recently added to or reduced their stakes in the business. BlackRock Inc. bought a new position in shares of CeriBell in the second quarter valued at $37,657,000. KCM Capital Inc boosted its stake in shares of CeriBell by 40.0% during the 1st quarter. KCM Capital Inc now owns 1,400,000 shares of the company's stock worth $25,662,000 after acquiring an additional 400,000 shares in the last quarter. Bank of New York Mellon Corp bought a new stake in shares of CeriBell during the 2nd quarter worth $17,437,000. TimesSquare Capital Management LLC bought a new stake in shares of CeriBell during the 2nd quarter worth $15,182,000. Finally, Goldman Sachs Group Inc. lifted its holdings in shares of CeriBell by 25.1% during the third quarter. Goldman Sachs Group Inc. now owns 350,570 shares of the company's stock valued at $8,550,000 after purchasing an additional 70,261 shares during the last quarter.
Wall Street Analysts Forecast Growth
CBLL has been the subject of several research analyst reports. Weiss Ratings upgraded CeriBell from a "sell (e+)" rating to a "sell (d-)" rating in a report on Friday, October 16th. Canaccord Genuity Group raised their target price on CeriBell from $26.00 to $33.00 and gave the company a "buy" rating in a research note on Wednesday, November 4th. BTIG Research reaffirmed a "buy" rating on shares of CeriBell in a report on Wednesday, November 4th. Barclays upgraded shares of CeriBell to a "neutral" rating in a research report on Tuesday, August 18th. Finally, Raymond James Financial reissued a "strong-buy" rating and issued a $29.00 price target on shares of CeriBell in a report on Thursday, September 3rd. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, CeriBell presently has a consensus rating of "Moderate Buy" and a consensus target price of $31.25.
Read Our Latest Analysis on CeriBell
About CeriBell
(
Get Free Report)
Ceribell, Inc. develops neurodiagnostic technology for detecting and monitoring seizures. Its products are designed to make electroencephalography (EEG) more accessible in emergency departments and intensive care units, where timely assessment can be important and conventional EEG services may not be readily available. The company's Ceribell point-of-care EEG system combines a headband with electrodes, a portable recorder and software for viewing and analyzing EEG data. Its Clarity algorithm is designed to help clinicians identify patterns associated with seizure activity, while the system supports remote review by specialists.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider CeriBell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CeriBell wasn't on the list.
While CeriBell currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.